ONC Quote, Financials, Valuation and Earnings

Addex Therapeutics has a net margin of 0.11% compared to BeOne Medicines's net margin of -2841.85%. BeOne Medicines's return on equity of -11.54% beat Addex Therapeutics's return on equity of 91.08%.

BeOne Medicines has a consensus price target of $331.97, signalling upside risk potential of 20.05%. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 257.86%. Given that Addex Therapeutics has higher upside potential than BeOne Medicines, analysts believe Addex Therapeutics is more attractive than BeOne Medicines.

BeOne Medicines has a beta of 0.299, which suggesting that the stock is 70.143% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 1.620, suggesting its more volatile than the S&P 500 by 61.965%.

BeOne Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeOne Medicines pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.

BeOne Medicines quarterly revenues are $1.1B, which are larger than Addex Therapeutics quarterly revenues of $62.3K. BeOne Medicines's net income of $1.3M is higher than Addex Therapeutics's net income of -$1.8M. Notably, BeOne Medicines's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is 3.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeOne Medicines is 7.10x versus 22.91x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CRISPR Therapeutics AG has a net margin of 0.11% compared to BeOne Medicines's net margin of -106.6%. BeOne Medicines's return on equity of -11.54% beat CRISPR Therapeutics AG's return on equity of -18.65%.

BeOne Medicines has a consensus price target of $331.97, signalling upside risk potential of 20.05%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.67 which suggests that it could grow by 97.84%. Given that CRISPR Therapeutics AG has higher upside potential than BeOne Medicines, analysts believe CRISPR Therapeutics AG is more attractive than BeOne Medicines.

BeOne Medicines has a beta of 0.299, which suggesting that the stock is 70.143% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.751, suggesting its more volatile than the S&P 500 by 75.105%.

BeOne Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeOne Medicines pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

BeOne Medicines quarterly revenues are $1.1B, which are larger than CRISPR Therapeutics AG quarterly revenues of $35M. BeOne Medicines's net income of $1.3M is higher than CRISPR Therapeutics AG's net income of -$136M. Notably, BeOne Medicines's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeOne Medicines is 7.10x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of 0.11% compared to BeOne Medicines's net margin of 26.48%. BeOne Medicines's return on equity of -11.54% beat Novartis AG's return on equity of 30.96%.

BeOne Medicines has a consensus price target of $331.97, signalling upside risk potential of 20.05%. On the other hand Novartis AG has an analysts' consensus of $112.64 which suggests that it could fall by -6.73%. Given that BeOne Medicines has higher upside potential than Novartis AG, analysts believe BeOne Medicines is more attractive than Novartis AG.

BeOne Medicines has a beta of 0.299, which suggesting that the stock is 70.143% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.595, suggesting its less volatile than the S&P 500 by 40.528%.

BeOne Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 3.31% to investors and pays a quarterly dividend of $3.99 per share. BeOne Medicines pays -- of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BeOne Medicines quarterly revenues are $1.1B, which are smaller than Novartis AG quarterly revenues of $13.6B. BeOne Medicines's net income of $1.3M is lower than Novartis AG's net income of $3.6B. Notably, BeOne Medicines's price-to-earnings ratio is -- while Novartis AG's PE ratio is 18.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeOne Medicines is 7.10x versus 4.57x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

Roche Holding AG has a net margin of 0.11% compared to BeOne Medicines's net margin of --. BeOne Medicines's return on equity of -11.54% beat Roche Holding AG's return on equity of 23.8%.

BeOne Medicines has a consensus price target of $331.97, signalling upside risk potential of 20.05%. On the other hand Roche Holding AG has an analysts' consensus of $46.42 which suggests that it could grow by 10.65%. Given that BeOne Medicines has higher upside potential than Roche Holding AG, analysts believe BeOne Medicines is more attractive than Roche Holding AG.

BeOne Medicines has a beta of 0.299, which suggesting that the stock is 70.143% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.459, suggesting its less volatile than the S&P 500 by 54.134%.

BeOne Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Roche Holding AG offers a yield of 3.31% to investors and pays a quarterly dividend of $1.39 per share. BeOne Medicines pays -- of its earnings as a dividend. Roche Holding AG pays out 92.43% of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BeOne Medicines quarterly revenues are $1.1B, which are larger than Roche Holding AG quarterly revenues of --. BeOne Medicines's net income of $1.3M is higher than Roche Holding AG's net income of --. Notably, BeOne Medicines's price-to-earnings ratio is -- while Roche Holding AG's PE ratio is 29.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeOne Medicines is 7.10x versus 3.84x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.